A study conducted by Dr. S. Pant at MD Anderson to characterize the safety and early signs of efficacy of lixumistat in combination with standard of care in patients with advanced pancreatic cancer recently completed (NCT05497778). This study defined the RP2D and provided impressive interim evidence of clinical activity (ESMO GI, July 2025).
Lixumistat in combination with gemcitabine and nab-paclitaxel (standard of care) in patients with advanced PDAC. Principal Investigator: Dr. Shubham Pant, MD Anderson Cancer Center. Registry: NCT05497778.
Among the first 10 evaluable patients at the RP2D, the clinical response (ORR) and disease control (DCR) rates were 50% and 80%, respectively. Median progression free survival (PFS) and overall survival (OS) were 7.4 and 18 months, respectively. Importantly, there were no dose limiting toxicities observed at the RP2D.
Data presented at ESMO GI (July 2025). Interim publication in progress.
Proof of concept in pancreatic cancer, with glioblastoma as the next planned indication. We welcome conversations with investors and partners.
